Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

Sanofi appoints ex-Roche Reed as new R&D head

The Paris-headquartered firm also secured two major acquisitions in January, buying US haemophilia specialist Bioverativ for $11.6 billion and Belgium’s next-generation biologics firm Ablynx for 3.9

Latest news

Sanofi sells European generics to Advent for $2.4bn

The restructuring has already seen it bolster its pipeline in rare diseases with the acquisitions of Bioverativ for $11.6bn and Ablynx for 3.9bn after missing out on earlier bids
Sanofi taps Evotec for new anti-infectives drive

the French drugmaker, which is in the midst of a major revamp of its pipeline following the acquisitions of Ablynx and Bioverativ.
Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

This is the second major acquisition by Sanofi in as many weeks, coming after the French pharma major agreed an $11.6bn acquisition of Bioverativ. ... Both deals boost its positions in rare diseases and haematology, with Ablynx’lead product
Biogen cuts $217m deal for Karyopharm neurology drug

its haemophilia and other rare blood disorders business into a new company called Bioverativ last year (since acquired by Sanofi).
Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Sanofi is offering $105 apiece for all of Bioverativ’s outstanding shares, which is a two-thirds premium on the US-based company’s closing price ahead of the weekend. ... Bioverativ separated from Biogen last year to create a stand-alone haemophilia

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... Paying $105 per share in cash (64% premium over Bioverativ’s closing price on

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Medical Writer: Great salary and benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Scientific Director: Great salary and bebefits

Senior Account Manager or AD - Medical Communications: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Programme Executive: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Subscribe to our email news alerts

PMHub

Add my company

CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...
The Holy Grail of HCP Access: This is the data you need to gain access....